期刊文献+

胃腺癌血管活性肠肽受体mRNA表达的研究

Vasoactive intestinal peptide receptor mRNA expression in gastric adenocarcinoma
下载PDF
导出
摘要 目的研究血管活性肠肽受体mRNA在胃腺癌组织和AGS人胃腺癌细胞中的表达情况,探讨其在胃腺癌发病过程中的作用。方法采用RT-PCR方法,检测24例胃腺癌组织、24例正常胃腺组织及不同传代AGS人胃腺癌细胞中VIPR mRNA的表达。结果胃腺癌患者组VIPR1 mRNA表达率为45.00%(9/24),低于正常对照组的83.33%(20/24)(P<0.05);VIPR2 mRNA表达率在胃腺癌患者组和正常对照组分别为50.00%(10/24)和66.67%(16/24),差异无统计学意义(P>0.05)。与正常胃窦黏膜比较,VIPR1 mRNA的表达量下降(P<0.05),但VIPR2 mRNA的表达量和正常胃窦黏膜差异无统计学意义(P>0.05)。不同传代AGS人胃腺癌细胞中均有VIPR mRNA的表达,但传代细胞之间差异无统计学意义(P>0.05)。结论VIPR mRNA的低表达可能与胃腺癌的发生发展有关,检测VIPR mRNA表达对胃腺癌的诊断具有一定的指导意义。 Objective To investigate the expression of vasoactive intestinal peptide receptor ( VIPR) mRNA in gastric adenocarcinoma and AGS cells , and understand the effect of VIPR on gastric adenocarcinoma and possible mechanism.Methods Gastric tissues of 24 patients with gastric adenocarcinoma and 24 healthy controls were collected, and the expression of VIPR mRNA was determined by real time PCR .The VIPR mRNA expression was also detected in gastric adenocarcinoma cell line ACG by the same way .Results The expression rate of VIPR1 mRNA was 45.00%(9/24)in gastric adenocarcinoma, which was significantly lower than controls 83.33%(20/24)(P〈0.05 ) , but that of VIPR2 mRNA didn′t changed significantly ( 50.00% vs 66.67% ) ( P〉0.05 ) .The levels of VIPR1 mRNA in gastric adenocarcinoma was lower than that in controls ( P〈0.05 ) , while there was no different in the levels of VIPR2 mRNA(P〉0.05).All of the AGS cells were positive both in VIPR1 and VIPR2 mRNA expression.Conclusion The lower level of VIPR mRNA expression may be an integral part in the pathogenesis of gastric adenocarcinoma , and VIPR mRNA detection may be contribute to the diagnosis of gastric carcinoma .
出处 《中国临床新医学》 2014年第7期579-583,共5页 CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金 国家自然科学基金资助项目(编号:81271851) 广西卫生厅科研课题(编号:Z2011349)
关键词 胃腺癌 血管活性肽受体 MRNA Gastric adenocarcinoma Vasoactive intestinal peptide receptor mRNA
  • 相关文献

参考文献14

  • 1Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of. cancer in 2008: GLOBOCAN 2008 [ J]. Int J Cancer,2010, 127 (12) :2893 -2917.
  • 2徐伟,赵亚华,孔洁.血管活性肠肽研究进展[J].药物生物技术,2002,9(6):364-368. 被引量:16
  • 3Kim SW, Beauchamp RD, Townsend CM Jr, et al. Vasoactive intes- tinal polypeptide inhibits c-myc expression and growth of human gas- tric carcinoma cells[J]. Surger,1991,110(2) :270 -275.
  • 4Lishi H, Tatsuta M, Baba M, et al. Enhancement by vaso-active in- testinal peptide of gastric carcinogenesis induced by N-methyl-N'-ni- tro-N-nitrosoguanidine in rats[ J]. Int J Cancer, 1992,50(4) :649 - 652.
  • 5张清媛.肿瘤学概论[M].北京:人民卫生出版社,2010.7.
  • 6徐海燕.血管活性肠肽的免疫调节作用[J].国外医学(免疫学分册),2002,25(2):73-76. 被引量:13
  • 7Reubi JC. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications [ J ]. Ann NY Acad Sei,2000, 921:1 -25.
  • 8Moody TW, Leyton J, Chan D, et al. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells [ J]. Breast Cancer Res Treat ,2001,68 (1) :55 -64.
  • 9Gelber E, Granoth R, Fridkin M, et al. A lipophilic vasoactive intes- final peptide analog enhances the antiproliferative effect of chemother- apeutic agents on cancer cell lines[J]. Cancer,2001,92(8) :2172 - 2150.
  • 10Heasley LE. Autocrine and paraerine signaling through neuropeptide receptors in human cancer[ J]. Oncogene Cancer,2001, 20 ( 13 ) : 1563 - 1569.

二级参考文献39

  • 1陈元方 张万岱 陈元方 主编.胃肠肽类激素、生长激素与消化系统非内分泌性恶性肿瘤[A].陈元方,主编.胃肠肽类激素基础与临床[C].北京:北京医科大学中国协和医科大学联合出版社,1997.750-765.
  • 2Heasley LE. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene, 2001, 20:1563-1569.
  • 3Kim SW, Beauchamp RD, Townsend CM Jr,et al. Visoactive intestinal polypeptide inhibits c-myc expression and growth of human gastric carcinoma cells. Surgery, 1991, 110 : 270-275.
  • 4Iishi H, Tatsuta M, Baba M, et al. Enhancement by vaso-active intestinal peptide of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats. Int J Cancer, 1992, 50:649-652.
  • 5Nagakawa O, Murata J, Junicho A, et al. Vasoactive intestinal peptide (VIP) enhances the cell motility of androgen receptor-transfected DU-145 prostate cancer cells (DU-145/AR). Cancer Lett,2002, 176: 93-99.?A
  • 6Heasley LE. Autocrine and paracrine signaling through neuropeptide receptors in human cancer.Oncogene, 2001, 20:1563-1569.?A
  • 7Reubi JC. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. clinical implications. Ann N Y Acad Sci, 2000, 921:1-25.
  • 8Hejna M, Hamilton G, Brodowicz T, et al. Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract. Anticancer Res, 2001,21:1183-1187.?A
  • 9Kim SW, Beauchamp RD, Townsend CM Jr,et al. Vasoactive intestinal polypeptide inhibits c-myc expression and growth of human gastric carcinoma cells. Surgery, 1991, 110: 270-276.?A
  • 10Delgado M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B,NF-AT, and early growth factors 2/3. J Immunol, 2001, 166:1028-1040.?A

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部